US Stock Reports, Quotes and News
Ramelius Resources (RMS.AX) has reported a record quarterly gold production, resulting in an upgraded full-year production guidance and a reduction in cost guidance. The company announced during its earnings call that it achieved a gold production of 86,928 ounces for the quarter, with an all-in sustaining cost of $1,344 per ounce.
Cadence Design Systems, Inc. (NASDAQ:CDNS) reported a robust first quarter in 2024, surpassing its own financial guidance with a total revenue of $1.009 billion. The company's strong performance is backed by significant design activity in key technology areas and a record backlog that positions it well for the future.
Novartis (SIX:NOVN) (NVSEF) shares surged 4.7% in European trading Tuesday after the Swiss pharmaceutical company's release of impressive first-quarter results.
FNB Corporation (NYSE: FNB) has reported a strong first quarter, with operating earnings per share at $0.34 and operating net income of $123 million. The company has seen significant growth in its loan and deposit portfolios, along with a nearly record level of non-interest income, thanks to its strategic investments and geographic expansion. FNB\’s asset quality metrics remain robust, and the company is optimistic about the second half of the year, expecting to benefit from a more favorable interest rate environment. Despite some increases in operating non-interest expense and a slight decline in net interest margin, FNB maintains its full-year guidance and continues to receive recognition for its service and performance.
Sandip Agarwal asks: \”Despite a strong TCV, why is the growth guidance so low? We are not able to connect the dots of what is pulling down growth so much and why they are projecting this kind of growth. In my view, this guidance and these numbers are on the lower side of what anyone would have been anticipating.\”
Profit climbed to ₹7,969 crore in the March quarter, beating ET\’s poll of ₹6,103 crore. Other income buttressed the bottom-line through what turned out to be a tough year for revenue expansion, which hit the lowest pace in a decade. Headcount shrank by about 26,000, again a rarity for India\’s technology bellwether.
Johnson & Johnson (NYSE:JNJ) reported mixed financial results for the first quarter of 2024, with adjusted earnings per share (EPS) slightly surpassing analyst expectations, while revenue fell marginally short of estimates. The healthcare giant posted an adjusted EPS of $2.71, which was $0.07 higher than the consensus estimate of $2.64. However, quarterly revenue was a hair\’s breadth away from consensus, coming in at $21.38 billion against the expected $21.4 billion.